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Abstract
Insulin-like growth factor-I (IGF-I) in human hepatoma cells
(HEP-G2) has, in addition to its effect on cell growth, short-
term metabolic effects acting through its own receptor. We
have demonstrated that normal human hepatocytes, compared
with HEP-G2 cells, have virtually no IGF-I binding sites. Be-
cause the rate of growth is the major difference between the
hepatoma and the normal liver, we asked if normal liver might
express IGF-I binding sites under physiologic growth condi-
tions. Indeed, whereas adult rat hepatocytes have low IGF-I
binding sites similar to those in human liver, hepatocytes from
regenerating liver after 3 d subtotal hepatectomy have an ap-
proximately sixfold increase (P < 0.005) and those from fetal
rat liver a - 12-fold increase (P < 0.005), to levels comparable
to those in the HEP-G2 cells. The specificity of 125I IGF-I
binding to its receptor was demonstrated by competition stud-
ies with monoclonal antibodies directed toward the IGF-I and
the insulin receptors, with unlabeled IGF-I and insulin and by
affinity labeling experiments. Thus, if IGF-I has any short-
term metabolic functions in the adult human liver, it is not
through interaction with its own receptor. Autocrine regulation
by IGF-I of liver growth appears possible since IGF-I binding
sites are expressed under pathological and physiological con-
ditions of growth. The mechanism that couples these two phe-
nomena remains to be elucidated.
Introduction
Insulin and the type-I insulin-like growth factor (IGF-I)' ex-
hibit a similar spectrum ofbiological activities and have a high
degree of sequence homology (1, 2). The primary event in the
action of IGF-I on target cells, similar to that of insulin, ap-
pears to be the binding to specific receptors on the cell surface
(2-4). The IGF-I receptor consists of heterotetrameric disul-
fide-linked subunits, the structure of which closely resembles
that of the insulin receptor (5, 6). Given these similarities, it is
not unexpected that insulin can react with the IGF-I receptor
and that IGF-I can react with the insulin receptor (7). Each
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hormone can react with the other's binding sites, but with
relatively reduced affinities (7). We have developed a method
to isolate insulin-responsive human hepatocytes from 1-2 g
intraoperative liver biopsy to study insulin action and resis-
tance in man (8). Thus, it is imperative to study IGF-I binding
and action in human liver to determine whether insulin-stimu-
lated biological events are mediated through the insulin recep-
tor or are due to IGF-I receptor occupation. This question is
particularly relevant as it has recently been shown in the fetal
rat hepatocytes that IGF-I was 20 times more potent than
insulin in stimulating glycogen synthesis (9, 10). Similarly, in
the human hepatoma cell line (HEP-G2), IGF-I stimulates
glycogen synthesis, and insulin over 100 pM appears to stimu-
late insulin action through interaction with the IGF-I binding
sites (1 1).
Methods
Materials. Recombinant IGF-I was purchased from AMGen Biologi-
cals, Thousand Oak, CA, and 125I IGF-I (2,000 Ci/mmol) from Amer-
sham Corp., Arlington Heights, IL. Crude collagenase (type IV, lot
25F6806) and deoxyribonuclease were obtained from Sigma Chemical
Co., St. Louis, MO; dispase from Boehringer Mannheim Biochemicals,
Indianapolis, IN; crude collagenase (4177 CLS II W2h202) and soy-
bean trypsin inhibitor from Worthington Biomedical Corp., Freehold,
NJ. Fraction V bovine serum albumin (BSA), obtained from Armour
Pharmaceutical Company, Kankakee, IL, was purified by charcoal
treatment (12). The following were gifts: monoclonal antibodies to the
human IGF-I receptors (aIR-I) from Dr. Steven Jacobs, Wellcome
Research Laboratory, Research Triangle Park, NC, monoclonal anti-
bodies to the human insulin receptors (51 BlO) from Dr. Richard A.
Roth, Stanford University School of Medicine, Stanford, CA, and
HEP-G2 cell line from Dr. B. Knowles, Wistar Institute, Philadelphia,
PA. Crystalline porcine insulin was a gift from Dr. Ronald Chouce of
Eli Lilly and Co., Indianapolis, IN.
Isolated hepatocytes. Human hepatocytes were isolated as pre-
viously described (8). The donors were a 35-yr-old female with morbid
obesity (weight 97 kg, height 155 cm) and without diabetes mellitus
(fasting plasma glucose, 93 mg/dl; fasting plasma insulin, 31 tU/ml;
peak plasma insulin during intravenous glucose tolerance test, 184
gU/ml; and kg rate 1.4%/min glucose disappearance) and a 50-yr-old
female with morbid obesity (95 kg, height 165 cm) and untreated
non-insulin-dependent diabetes mellitus (fasting plasma glucose, 194
mg/dl; fasting plasma insulin, 38 uU/ml; peak plasma insulin during
intravenous glucose tolerance test, 46 AU/ml; and kg rate 0.6%/min
glucose disappearance) undergoing an elective gastric bypass. The
subjects underwent surgery in the morning after an overnight fast. No
glucose was given intravenously before the liver biopsy. As soon as the
abdomen was opened and explored to demonstrate no contraindica-
tion to the surgical procedure, a 1-2-g liver biopsy was obtained from
the left lobe. Written consent was obtained from all patients after they
were informed about the nature and potential risks of the study.
HEP-G2 cells were obtained from Dr. B. Knowles, Wistar Institute,
Philadelphia, PA. The cells were cultured as described by Knowles et
al. (13). Experiments were performed 3-4 d after plating, when the
hepatocytes were still in the logarithmic phase of growth.
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Rat hepatocytes were isolated, as we have previously described
(14), from adult normal male Sprague-Dawley rats, from regenerating
liver after 1-4 d subtotal hepatectomy as described by Blachard et al.
(15), and from 20 d gestation fetal Sprague-Dawley rats as described by
Sinha et al. (16).
Liver plasma membranes. Liver plasma membranes were prepared
from six male Sprague-Dawley rats on the third day after subtotal
hepatectomy and their sham-operated, pair-fed controls, from three
20-d gestational fetal Sprague-Dawley rats, and from three human
brain-dead organ donors who had no previous history ofany metabolic
disease. The liver tissue was homogenized in 1 mM NaHCO3 buffer,
containing 0.5 mM CaCl2 (pH 7.5) as described by Ray (17), with the
addition of 2 AM leupeptin, 2 AM pepstatin, 1 mM penylmethylsul-
fonyl fluoride, 0.1 mg/ml bacitracin, and 1,000 U/ml aprotinine. The
plasma membranes were isolated by the aqueous two-phase polymer
method of Lesko et al. (18) with minor modifications (8). The mem-
branes were suspended in 50 mM Hepes buffer (pH 7.4) and kept at
-70°C until they were used.
125I IGF-I binding. Hepatocytes (- 1 X 106 cells/ml) were sus-
pended in Hanks'-Hepes buffer (pH 7.4) containing 8 mM glucose and
10 mg/ml BSA. HEP-G2 cells were either detached from the culture
plates and suspended as described, or studied while adhered to 35-mm
plastic tissue culture dishes (- 200 Mg cell protein or - 106 cells per
dish). Plasma membranes (250 Mg) were suspended in 250 ,l of Krebs-
Ringer bicarbonate buffer (pH 7.4) containing 10 mg/ml BSA. To
measure IGF-I binding, hepatocytes were incubated at 20°C with 1251I
IGF-I 50 pM in the presence of increasing concentrations of unlabeled
hormone. After the desired duration of incubation, the cells or mem-
branes were centrifuged, the incubation medium removed, and the
pellets washed twice at 4°C with fresh medium. Nonspecific binding
was determined by incubation in the presence of 50 nM unlabeled
IGF-I. Specific binding was calculated by subtracting nonspecific bind-
ing from total binding. An aliquot of the incubation medium was
counted to determine the quantity of unbound IGF-I. To determine
1251I IGF-I degradation, 10% TCA was added to a portion of the incu-
bation medium. The percentage of IGF-I degraded was calculated
by dividing the total counts per minute precipitated by TCA and sub-
tracting this from one.
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Initial experiments were performed to determine optimal condi-
tions under which to study IGF-I binding. At 20°C, maximum IGF-I
binding plateaued from 60 to 240 min. Thus, the binding studies
described in this report were performed at 20°C for 120 or 180 min.
Under these conditions, nonspecific binding and ligand degradation
were < 20% of total IGF-I binding and free IGF-I in the incubation
medium, respectively. Furthermore, IGF-I binding was linear over a
range of0.5-2 x 106 isolated hepatocytes and 100-250 Mg liver plasma
membrane.
Affinity labeling ofthe IGF-I receptor. Following optimal 1251 IGF-I
binding in the absence and presence ofunlabeled IGF-I (1 X 10-9M to
I X 10-6 M) and unlabeled insulin (1 X l0-9 M to I X 10-6 M) to liver
plasma membranes as described in the preceding section, the 1251I IGF-I
receptor complex was covalently cross-linked with 0.5 mM disuccini-
midyl suberate for 10 min at 4°C by the method of Pilch and Czech
(19). The reaction was stopped by adding 50 mM Tris HCI (pH 7.0)
containing 1% SDS, 0.005 bromophenol blue, 2% glycerol, and 50mM
dithiothreitol and boiling for 3 min. Polyacrylamide gel electrophoresis
was performed according to the method of Laemmli (20) in 7.5%
polyacrylamide slab gels. Then the gels were stained, destained, dried,
and autoradiographed with Kodak X-OMAT film using lightening
plus-screen.
12-I insulin binding. 25I insulin binding was performed in liver
plasma membranes from the experimental groups as previously de-
scribed (8).
Statistical analysis. Descriptive statistics (mean±SEM) and com-
parative statistics (analysis of variance and t tests) were performed
using a computerized program (Stat View, the graphic statistics for the
Apple Macintosh).
Results
Fig. 1 shows the competitive binding studies of 1251 IGF-I in
HEP-G2 cells and human hepatocytes. This figure demon-
strates that HEP-G2 cells, a minimal deviation human hepa-
toma, have specific 1251I IGF binding sites as previously re-
ported by Verspohl et al. (1 1). In contrast, Fig. 1 clearly shows
that human hepatocytes have no detectable specific IGF-I
binding. The human cells are morphologically intact with over
90% excluding trypan blue. These cells incorporate [14C]-
leucine into proteins linearly for at least 2 h; most importantly,
we have previously shown that they respond to insulin in re-
gard to lipid synthesis and amino acid transport, and have a
similar number of insulin receptors as do rat hepatocytes (8).
Fig. 2 further substantiates the specificity of IGF-I binding to
HEP-G2 cells, as increasing concentrations of monoclonal an-
tibodies to the IGF-I receptors compete in a dose-dependent
manner with 1251 IGF-I for the binding sites, whereas maximal
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Figure 1. 125I IGF-I binding in HEP-G2 cells and isolated human he-
patocytes. Cells (- 1 X 106 cells/ml) were incubated with 50 pM 1251
IGF-I and increasing concentrations of unlabeled IGF-I for 120 min
at 20°C in Hanks' Hepes buffer, pH 7.4, supplemented with 8 mM
glucose and 10 mg/ml BSA. Free 1251 IGF-I was separated from
bound by extensive washing with fresh incubation buffer at 4°C. The
data are expressed as percent specific binding per 1 X 106 cells. The
data in HEP-G2 cells represent the mean±SEM of four separate de-
terminations and those from humans with and without non-insulin-
dependent diabetes mellitus (NIDDM) are the mean of triplicate
samples.
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Figure 2. Effect of
monoclonal antibodies
to the IGF-I and insulin
receptors on 125I IGF-I
binding. 1251 IGF-I
binding was performed
in the HEP-G2 cells, as
described in the legend
of Fig. 1, in the pres-
ence and absence of dif-
ferent concentrations of
monoclonal antibodies
to the IGF-I and insulin
receptors. The data are
the mean±SEM of four
separate determinations.
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concentration of monoclonal antibodies to the insulin recep-
tors had no effect.
Thus, a tissue from the same species under pathological
conditions expresses a different amount of IGF-I binding sites.
The major distinction between HEP-G2 cells and normal liver
is the former's pathological growth rate and the fact that it has
been maintained in culture. We then asked if normal liver
could express IGF-I binding under physiological growth con-
ditions. Fig. 3 attempts to answer this question. Freshly iso-
lated hepatocytes from fetal rat liver have as much specific 125I
IGF-I binding as did the HEP-G2 cells. I251GF-I binding in
fetal rat hepatocytes was statistically higher (P < 0.01-0.005)
than the other experimental groups shown in Fig. 3. As pre-
viously shown by Massague and Czech in liver plasma mem-
branes (7), freshly isolated hepatocytes from adult rat liver
have extremely low, if any, IGF-I binding sites. Furthermore,
IGF-I binding remained < 1% in primary cultures of adult rat
hepatocytes for up to 48 h. However, freshly isolated hepato-
cytes from regenerating adult rat liver after subtotal hepatec-
tomy, have a significant increase in IGF-I binding that is
maintained for up to 4 d when compared with normal adult
hepatocytes (day 1-2, P < 0.05; day 3, P < 0.005; day 4 P
< 0.025). Insulin-like growth factor-I binding in liver after 3 d
subtotal hepatectomy is higher than that from day 4 (P
< 0.025), but it is not different from that from day 1-2; like-
wise, day 1-2 is not statistically different from that from day 4.
The advantages of using isolated hepatocytes is that they
allow the selection of parenchymal cells. This is particularly
true in the case of fetal liver, which contains a significant
amount of hematopoetic tissue. A potential pitfall of this ap-
proach, however, is that the methodologies necessary to isolate
human hepatocytes, adult rat hepatocytes, and fetal rat hepa-
tocytes are significantly different, particularly since each re-
quires a different type of collagenase. Thus, the changes ob-
served could be due to differences in survival of the IGF-I
receptor to a specific cell isolation procedure or collagenase
type. To address this question, we prepared liver plasma
membranes to study IGF-I binding, not from isolated hepato-
cytes, but from the liver. Furthermore, we introduced a sham-
operated, control pair fed with the hepatectomized rats, since
the increase in IGF-I binding in the regenerating liver could
have been due to stress or nutritional factors.
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Figure 3. 1251I IGF-I binding in adult, regenerating, and fetal rat hepa-
tocytes. 125I IGF-I binding was performed in isolated hepatocytes de-
rived from fetal and adult rats, and adult rats 1-2, 3, and 4 d after
subtotal hepatectomy, as described in the legend of Fig. 1. The data
represent the mean±SEM of three or five separate experiments.
Fig. 4 shows the data generated in liver plasma mem-
branes. Fetal rat liver has statistically higher (P < 0.005) IGF-I
binding when compared with liver from each of the other
groups. Adult rat liver from 3 d after subtotal hepatectomy
also has higher (P < 0.05) IGF-I binding than the respective
sham-operated pair fed control. IGF-I binding in this adult rat
control was no different from that found in adult human liver.
The inset in Fig. 4 is a Scatchard plot of the data that suggests
that the changes in IGF-I binding are mainly due to differences
in the number of binding sites. However, since insulin and
IGF-I cross-react with each others' receptor and it is known
that there are differences in 125I insulin binding among fetal rat
liver (16), regenerating liver (21), and adult liver, 1251 insulin
binding was also measured in the same liver plasma mem-
brane as shown in Fig. 5. It can be seen that the regenerating
liver had approximately a half-fold increase in insulin binding
when compared with the control; this difference was signifi-
cant (P < 0.05) at the three lowest concentrations of insulin
used, whereas the increase in IGF-I binding was approximately
threefold (Fig. 4). Likewise, insulin binding in the human liver
was similar to that in the rat liver, but IGF-I binding was
extremely low. The increase in insulin binding in the fetal liver
was approximately fourfold, whereas it was sixfold for IGF-I
binding compared with the adult rat liver (Fig. 4). Thus, the
changes in insulin binding observed cannot explain the data
on IGF-I binding, particularly considering the limited cross-re-
activity of insulin with the IGF-I receptor and of IGF-I with
the insulin receptors (7). However, it should be recognized
that, although to varying degrees, insulin and IGF-I binding
are increased in regenerating and fetal rat liver. This is not
surprising since both hormones exhibit a similar spectrum of
biological activities and it is not a universal finding for other
receptors (21).
To exclude the possibility that 1251 IGF-I was interacting to
a significant degree with the type II IGF receptor, we affinity
labeled 1251IGF-I to the plasma membranes. Figs. 6 and 7 dem-
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Figure 4. 1251 IGF-I binding in fetal, regenerating, and adult rat and
adult human liver plasma membranes. Liver plasma membranes
(250 gg/protein) were incubated in Krebs-Ringer bicarbonate buffer
containing 10 mg/ml BSA in the presence of 125I IGF-I (50 pM) and
increasing concentrations of unlabeled IGF-I for 3 h at 20°C. Then
the membranes were separated from the medium by centrifugation,
washed, and the radioactivity counted as described in the Methods
section. The data represent the mean±SEM of percent specific 125I
IGF-I binding at tracer concentration (50 pM) from 3 or 4 separate
experiments and a representative Scatchard plot of these data.
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Figure 5. 12"I insulin binding to fetal, regenerating, and adult rat, and
adult human liver plasma membranes. Liver plasma membranes
were incubated in Krebs-Ringer bicarbonate buffer containing 10
mg/ml BSA in the presence of 1 X 1010 M '25I insulin and increas-
ing concentrations of unlabeled insulin for 3 h at 20°C. Then the
membranes were separated from the medium by centrifugation,
washed, and the radioactivity counted as described in Methods.
onstrate that incubation of liver plasma membranes from the
regenerating and fetal rat liver, respectively, with 1251 IGF and
subsequent addition ofdisuccinimidyl suberate under reduced
conditions labeled a protein of an approximate molecular
mass of 130,000 D, which corresponded to the molecular mass
of the a-subunit of the IGF-I receptor. Since the a-subunit of
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Figure 7. Autoradiogram of the a-subunit composition of the re-
duced IGF-I receptors in 3-d regenerating rat liver. '25I-IGF-I binding
was performed in plasma membranes from fetal rat liver as described
in the legend of Fig. 4 in the absence and presence of increasing con-
centrations of unlabeled IGF-I and insulin. The 1251I-IGF-I receptor
complex was crosslinked with 0.5 mM disuccinimidyl suberate, re-
duced with 50 mM dithiothreitol, and subjected to SDS-PAGE fol-
lowed by autoradiography.
the insulin receptor has a molecular mass similar to that of the
IGF-I receptor, the same figure demonstrates that concentra-
tions of unlabeled IGF-I between X 10-8 M and X lO-' M
totally displaced the radioactivity of these bands, whereas con-
centrations of unlabeled insulin as high as X 1O-6 M resulted
in only minimal displacement, supporting the specificity ofthe
IGF-I binding. Because of the low IGF-I binding in adult liver
from human and rat, affinity labeling experiments could not
be performed adequately. Finally, affinity labeling experi-
ments of 1251I insulin in the absence and presence of unlabeled
IGF-I and insulin similarly showed the limited cross-reactivity
between IGF-I and the insulin receptor in these experimental
groups (data not shown).
Discussion
_
1 16- <
66-
1251-IGF-I + 0 -9 -8 -7 -6 -9 -8 -7 -6
Unlabeled
IGF-I (M)
Unlabeled
Insulin (M)
Figure 6. Autoradiogram of the a-subunit composition of the re-
duced IGF-I receptors in fetal rat liver. '251-IGF-I binding was per-
formed in plasma membranes from fetal rat liver as described in the
legend of Fig. 4 in the absence and presence of increasing concentra-
tions of unlabeled IGF-I and insulin. The 1251 IGF-I receptor com-
plex was crosslinked with 0.5 mM disuccinimidyl suberate, reduced
with 50 mM dithiothreitol, and subjected to SDS-PAGE followed by
autoradiography.
The main goal of this study was to begin to clarify the role of
IGF-I in the metabolic regulation of the human liver. This
effort was prompted by the observation of Verspohl et al. ( 11)
that in HEP-G2 cells, a proposed model for the human liver,
IGF-I had important short-term effects on metabolic functions
acting through its own receptor. We have demonstrated in this
study that the liver from adult humans has virtually no IGF-I
binding sites. Thus, if IGF-I has any effect on the adult human
liver, it is by interacting with other receptors or mediated by
some other factors. Given this important difference between
the transformed HEP-G2 cells and human liver, the use of
HEP-G2 cells as a model of the human liver should be quali-
fied.
It is well-demonstrated that IGF-I has potent long-term
growth effect. In this regard, it is interesting that the adult
human liver is devoid of IGF-I binding sites, similar to the
livers of adult rat and mouse, as we and others have shown (7).
In contrast, chick embryo hepatocytes (22), HEP-G2 cells (1 1),
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BRL 3A2 rat liver cells (23), rat hepatoma HTC cells (24), fetal
liver (25), and regenerating rat liver that have rapid rates of
growth express IGF-I binding sites. A notable exception, per-
haps, is the rat H-35 hepatoma, which does not have IGF-I
receptors (7), although IGF-I actions are mediated throughout
the insulin recpptors (26).
The liver is, however, the source of IGF-I, whether or not
IGF-I receptors are present (27, 28). Thus, it is possible that
once IGF-I receptors are expressed in the cell membrane, au-
tocrine interaction ofthe hormone with its own receptor stim-
ulates liver proliferation. Under regulated growth conditions,
this initial step might be followed by down-regulation of the
IGF-I receptors, an event that might not be operative under
pathological growth conditions. This is consistent with our
observation that incubation ofHEP-G2 cells with monoclonal
antibodies to the IGF-I receptors decreases cell proliferation
(unpublished data). Furthermore, Unterman and Phillips (29)
have recently demonstrated that IGF-I production by the re-
generating rat liver is enhanced. In vitro studies also have
shown that IGF-I stimulates the protein synthesis (30) and
proliferation (31) of hepatocytes. Consistent with this notion is
the finding that hypophysectomy retards hepatic regeneration
(32), which can be improved by the administration of growth
hormone.
IGF-I binding sites have been described in several human
and nonhuman tissues (2-7, 11, 22, 33-40). The biological
significance of the short-term effect of IGF-I on metabolic
function in physiology and pathology in man is unclear at this
time. If IGF-I plays any role, however, in the adult human
liver, it is by interacting with other binding sites, because IGF-I
binding is not present.
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